Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The synaptic vesicle glycoprotein 2A (SV2A), a protein essential to the proper nervous system function, is found in presynaptic vesicles. Thus, SV2A targeting, using dedicated radiotracers combined with positron emission tomography (PET), allows the assessment of synaptic density in the living brain. The first-in-class fluorinated SV2A specific radioligand, [ 18 F]UCB-H, is now available at high activity through an efficient radiosynthesis compliant with current good manufacturing practices (cGMP). We report here a noninvasive method to quantify [ 18 F]UCB-H binding in rat brain with microPET. Validation study in rats confirmed the need of high enantiomeric purity to target SV2A in vivo. We demonstrated the reliability of a population-based input function to quantify SV2A in preclinical microPET setting. Finally, we investigated the in vivo metabolism of [ 18 F]UCB-H and confirmed the negligible amount of radiometabolites in the rat brain. Hence, the in vivo quantification of SV2A using [ 18 F]UCB-H microPET seems a promising tool for the assessment of the synaptic density in the rat brain, and opens the way for longitudinal follow-up in neurodegenerative disease rodent models.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three of the SV2A ligands were radiolabeled as [ 11 C] UCB-A [112], [ 18 F]UCB-H [113-116], and [ 11 C]UCB-J [117], and all were evaluated in nonhuman primates (NHP).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [114]
Citations
Cites
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Molecular machines governing exocytosis of synaptic vesicles
Jahn, R., & Fasshauer, D. (2012) · Nature · doi:10.1038/nature11320 · Cited by 970
PET radiotracers: crossing the blood–brain barrier and surviving metabolism
Pike, V. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.005 · Cited by 582
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Self-citationDifferential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Graphical analysis of PET data applied to reversible and irreversible tracers
Logan, J. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00137-2 · Cited by 416
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296
Self-citation
Cited by
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
“We and other labs have tested [(11)C]UCB-A (2) [27], [(18)F]UCB-H (3) [8,92,93], and [(11)C]UCB-J (4) [65] (Fig.”
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“Numerous studies were performed to synthetize, evaluate and validate radiolabeled UCB-A (Estrada et al., 2016) and UCB-H (Bretin et al., 2013, 2015; Warnock et al., 2014; Warnier et al., 2016; Becker et al., 2017; Serrano et al., 2019a,b).”
BackgroundIn vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography
Bastin, C., Bahri, M. A., Meyer, F., Manard, M., Delhaye, E., Plenevaux, A., Becker, G., Seret, A., Mella, C., Giacomelli, F., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04461-x · Cited by 123
Self-citationImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“…novel PET radiotracers selectively targeting SV2A have been developed (Figure 8) (Mercier et al., 2014; Estrada et al., 2016; Nabulsi et al., 2016; Becker et al., 2017; Li et al., 2019; Cai et al., 2020a), enabling non-invasive observation and quantification of synaptic density in humans (Finnema…”
BackgroundSynaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
Constantinescu, C. C., Tresse, C., Zheng, M., Gouasmat, A., Carroll, V. M., Mistico, L., Alagille, D., Sandiego, C. M., Papin, C., MAREK, K. L., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1260-5 · Cited by 80
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
“In 2013, the creation of the first PET-suitable radiotracer, [18F]UCB-H, allowed the in vivo measurement of changes in SV2A brain levels in both humans and animals (Bretin et al., 2013; Warnock et al., 2014; Becker et al., 2017; Serrano et al., 2018).”
BackgroundMeasuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61
“[(18)F]UCB-H was shown to have negligible amount of radiometabolites in the rat brain [17].”
BackgroundSelf-citationLi, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Self-citationMercier, J., Provins, L., & Valade, A. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.003 · Cited by 59
Self-citationCai, Z., Li, S., Zhang, W., Pracitto, R., Wu, X., Baum, E., Finnema, S. J., Holden, D., Toyonaga, T., Lin, S.-F., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00618 · Cited by 54
Quantitative Rodent Brain Receptor Imaging
Herfert, K., Mannheim, J. G., Kuebler, L., Marciano, S., Amend, M., Parl, C., Napieczyńska, H., Maier, F. M., Vega, S. C., & Pichler, B. J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01368-9 · Cited by 47
Zheng, C., Holden, D., Zheng, M.-Q., Pracitto, R., Wilcox, K. C., Lindemann, M., Felchner, Z., Zhang, L., Tong, J., Fowles, K., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05597-5 · Cited by 35
“Among the available SV2A PET tracers, [C]UCB-A was arguably the most metabolically stable, even though its prevalent radiometabolite species in the plasma were not identified yet [26, 27].”
The Rise of Synaptic Density PET Imaging
Becker, G., Dammicco, S., Bahri, M. A., & Salmon, E. (2020) · Molecules · doi:10.3390/molecules25102303 · Cited by 31
“The first step for a non-invasive quantification of UCB-H in rat brain used a population-based input function (PBIF) [37].”
MethodInfluentialSelf-citationTechnical opportunities and challenges in developing total-body PET scanners for mice and rats
Du, J., & Jones, T. (2023) · EJNMMI Physics · doi:10.1186/s40658-022-00523-6 · Cited by 38
PET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 32
Navacerrada, M. E. S., Bahri, M. A., Becker, G., Seret, A., Germonpré, C., Lemaire, C. F., Giacomelli, F., Miévis, F., Luxen, A., Salmon, É., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01488-7 · Cited by 24
Self-citationPET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 19
Guan, B., Zhou, N., Wu, C., Li, S., Chen, Y., Debnath, S., Hofstad, M. E., Ma, S., Raj, G. V., He, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313085 · Cited by 16
“,11C-UCB-A [46], 11C-UCB-J [47], 18F-UCB-H [48], and 18F-SDM-8/SynVesT-1/2 [49,50]) have been reported for synaptic density PET imaging of neurodegenerative diseases [51,52], we performed a PET imaging evaluation in an NEPC xenograft model using 18F-SynVesT-1, after having confirmed SV2A protein expression in NEPC cel…”
MethodPreclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
Thomsen, M. B., Schacht, A. C., Alstrup, A. K. O., Jacobsen, J., Lillethorup, T. P., Bærentzen, S. L., Noer, O., Orłowski, D., Elfving, B., Müller, H. K., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01506-8 · Cited by 15
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Navacerrada, M. E. S., Bahri, M. A., Becker, G., Seret, A., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., Luxen, A., & Plenevaux, A. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1301-0 · Cited by 16
Self-citationNavacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 13
“Keywords: SV2A; SV2B; SV2C; microPET; [18F]UCB-H; epilepsy; PBIF; distribution volume; blocking assay; preclinical imaging”
MethodResultInfluentialSelf-citationPracitto, R., Wilcox, K. C., Lindemann, M., Tong, J., Zheng, C., Li, S., Finnema, S. J., Huang, Y. H., & Cai, Z. (2021) · ACS Omega · doi:10.1021/acsomega.1c02433 · Cited by 6
The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain
Goutal, S., Guillermier, M., Becker, G., Gaudin, M., Bramoullé, Y., Luxen, A., Lemaire, C. F., Plenevaux, A., Salmon, É., Hantraye, P., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00777-8 · Cited by 8
Self-citationJiang, Z., Cheng, X., Chen, H., Zheng, W., Sun, Y., Yu, Z., Yang, T., Zhang, L., Fan, D., Yang, Z., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00062 · Cited by 5
GPU-Based Real-Time Software Coincidence Processing for Digital PET System
Shi, Y. J., Meng, F., Zhou, J., Li, L., Li, J., & Zhu, S. (2021) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2021.3123875 · Cited by 3
“It is widely used in clinical diagnosis [1]–[4] and preclinical research [5]–[9] considering its performance on functional imaging through quantitatively assessing the”
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Goutal, S., Guillermier, M., Becker, G., Gaudin, M., Bramoullé, Y., Luxen, A., Lemaire, C. F., Plenevaux, A., Salmon, É., Hantraye, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14385090
Self-citationQiao, Z., Li, S., Zhang, Y., Zhao, X., Yang, Z., Sun, X., Chen, H., Cheng, X., Liu, Y., Ai, L., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c01052
Metadata
- Authors
- Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A.
- Affiliations
- University of Liège (BE)
- GIGA Cyclotron Research Centre In Vivo Imaging, University of Liège, 4000 Liège, Belgium
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Becker, Guillaume
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-07-13
- Volume
- 14
- Issue
- 8
- Pages
- 2719-2725
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2665902388
- Cited by
- 31
- References
- 30
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 5 · 2021: 7 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 2
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Universit? de Li?ge (13/17-07)
- European Regional Development Fund
- R?gion Wallonne
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- SV2A, PET radiopharmaceuticals, pharmacokinetics, radiometabolites, enantiomeric purity, input function, synaptic density, small animal PET, rat brain, radiotracer synthesis, neurodegenerative disease models
- MeSH terms
- Animals, Brain, Fluorine Radioisotopes, Male, Pyrrolidinones, Reproducibility of Results, Radiopharmaceuticals, Positron-Emission Tomography, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.